News summary

How tech billionaires are disrupting biomedical science

Source: Nature - Main • Published: 21 Oct 2026, 00:00

Summarized by Masters of Longevity from Nature - Main.

Analysis of how newly minted tech wealth and philanthropy are reshaping biomedical research priorities, funding models, and institutional influence.

How tech billionaires are disrupting biomedical science
Key Takeaways
  • Two giants of artificial intelligence, OpenAI and Anthropic, plan to go public in the next year or so, floating stocks that are expected to rocket some of their employees into the ranks of the ultra-wealthy.
  • Some analysts have projected that Anthropic’s initial public offering (IPO) might bring in US$2 trillion, the largest in history.
  • OpenAI is reportedly targeting $1.4 trillion for its IPO, although the company delayed going public until 2027 amid renewed concerns about AI safety.
Read the full article at Nature - Main ↗

Continue exploring

Recommended MoL Picks

MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.